The company is undervalued at 8.45 per share with modest projections ahead. The firm shows a Beta (market volatility) of -0.1456, which signifies not very significant fluctuations relative to the market. Let's try to break down what Benitec's beta means in this case. As returns on the market increase, returns on owning Benitec Biopharma are expected to decrease at a much lower rate. During the bear market, Benitec Biopharma is likely to outperform the market. Even though it is essential to pay attention to
Benitec Biopharma historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards foreseeing any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Benitec Biopharma Limited exposes twenty-eight different technical indicators, which can help you to evaluate its performance.
Benitec Biopharma has an expected return of -0.0353%. Please be advised to confirm Benitec Biopharma
sortino ratio,
skewness,
price action indicator, as well as the
relationship between the
potential upside and
rate of daily change to decide if
Benitec Biopharma stock performance from the past will be repeated at some point in the near future.
The performance of Benitec Biopharma Ltd in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Benitec Biopharma's
stock prices. When investing in Benitec Biopharma, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Benitec Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Benitec Biopharma carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
How important is Benitec Biopharma's Liquidity
Benitec Biopharma
financial leverage refers to using borrowed capital as a funding source to finance Benitec Biopharma Ltd ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Benitec Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Benitec Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Benitec Biopharma's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Benitec Biopharma's total debt and its cash.
Benitec Biopharma Gross Profit
Benitec Biopharma Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Benitec Biopharma previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Benitec Biopharma Gross Profit growth over the last 10 years. Please check Benitec Biopharma's
gross profit and other
fundamental indicators for more details.
Detailed Perspective On Benitec Biopharma
The
market capitalization of Benitec Biopharma is $2.41 Billion. Almost 89.0 percent of Benitec Biopharma outstanding shares are held by regular investors with 0.48 (percent) owned by
insiders and only 10.1 % by
other corporate entities. Note, that even with negative
profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
| 2017 | 2018 | 2019 | 2020 (projected) |
Revenues USD | 280 K | 11.38 M | 13.09 M | 14.12 M | Revenues | 378 K | 16.16 M | 18.58 M | 20.05 M |
Ownership Breakdown
Retail Investors89.42% | | Institutions10.1% |
| Retail Investors | 89.42 |
| Insiders | 0.48 |
| Institutions | 10.1 |
Benitec Biopharma has 97 percent chance to finish above $6.54 in October
The coefficient of variation is down to -7126.84 as of today. As of the 4th of September, Benitec Biopharma shows the
mean deviation of 3.46, and Risk Adjusted Performance of
(0.013489). Benitec Biopharma
technical analysis gives you the methodology to make use of
historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen
technical drivers for Benitec Biopharma Limited, which can be compared to its rivals. Please confirm
Benitec Biopharma jensen alpha, as well as the
relationship between the potential upside and
skewness to decide if Benitec Biopharma is priced correctly, providing market reflects its regular price of 6.67 per share. Given that Benitec Biopharma has
jensen alpha of
(0.06), we suggest you to validate Benitec Biopharma Limited's prevailing market performance to make sure the company can sustain itself at a future point.
The Bottom Line
When is the right time to buy or sell Benitec Biopharma Limited? Buying stocks such as Benitec Biopharma isn't very hard. However, what challenging for most investors is doing it at the right time. Proper market timing is something most people cannot do without
sophisticated tools, which help to isolate the right opportunities, deliver winning trades and diversify portfolios on a daily bases. To summarize, as of the 4th of September 2020, our current 30 days Buy-Hold-Sell recommendation on the company is
Cautious Hold. We believe Benitec Biopharma is currently
undervalued with
below average probability of financial unrest for the next two years.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of Benitec Biopharma Ltd. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com